

## Forward-looking Statements

This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like "expects," "estimates," "anticipates," "may," "believes," "feels" or similar words or expressions), for example, which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec's Annual Report on Form 10-K for the year ended December 31, 2015, Innospec's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors" in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

## Use of Non-GAAP Financial Measures

The information presented in this presentation includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States (GAAP). These non-GAAP financial measures comprise adjusted EBITDA, income before income taxes excluding special items and net income excluding special items and related per share amounts. Adjusted EBITDA is net income per our consolidated financial statements adjusted for the exclusion of charges for interest expense, net, income taxes, depreciation, amortization and acquisition fair value adjustments. Income before income taxes, net income and diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of foreign currency exchange losses/(gains), amortization of acquired intangible assets, adjustment to fair value of contingent consideration, acquisition-related costs, adjustment of income tax provisions, settlement of distributor claim and profit on disposal of subsidiary. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided herein and in the appendices below. The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company's underlying performance and identifying operating trends. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and the Company has determined that it is appropriate to make this data available to all investors. While the Company believes that such measures are useful in evaluating the Company's performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from similarly-titled non-GAAP financial measures used by other companies and do not provide a comparable view of the Company's performance relative to other companies in similar industries. Management uses adjusted EPS (the most directly comparable GAAP financial measure for which is GAAP EPS) and adjusted net income and adjusted EBITDA (the most directly comparable GAAP financial measure for which is GAAP net income) to allocate resources and evaluate the performance of the Company's operations. Management believes the most directly comparable GAAP financial measure is GAAP net income and has provided a reconciliation of adjusted EBITDA and net income excluding special items, and related per share amounts, to GAAP net income herein and in the appendices below.

## Innospec - Summary of $3^{\text {rd }}$ Quarter Performance

-Underlying business performance is right on track
One-off charges \& order phasing impact EPS in the short-term

- Fuel Specialties - strong growth in operating margin
-Performance Chemicals - innovation continues to drive great growth
-Oilfield Services - break even with modest market recovery
- Further increase in semi-annual dividend
-Acquisition of Huntsman European surfactant business on track for Q4.



## innospec

## Q3 2016 Consolidated Results

Sales below a very strong comparative quarter (Octane Additives; Oilfield Services)
Order phasing in Oilfield and Fuel Specialties; Gross Margin Improvement
One-off costs impacting EPS

|  | Q3 2015 <br> $\$ \mathbf{m}$ | Q3 2016 <br> $\$ \mathrm{~m}$ | Growth <br> $\%$ |
| :--- | ---: | ---: | ---: |
| Net sales | 254.2 | 205.5 | $(19) \%$ |
| Gross profit | 90.4 | 79.2 | $(12) \%$ |
| Gross margin | $35.6 \%$ | $38.5 \%$ | $2.9 \%$ pt |
| Operating income * | 31.1 | 16.6 | $(47) \%$ |
| Adjusted EBITDA | 42.1 | 21.2 | $(50) \%$ |
| EPS (diluted) | 1.45 | 0.47 | $(68) \%$ |
| EPS (adjusted) | 1.18 | 0.78 | $(34) \%$ |

*Operating Income is before Fair Value Adjustments and Profit on Disposal of Subsidiary
innospec

## Q3 2016 Fuel Specialties

Revenues lower in Americas, flat in EMEA, excellent growth in Asia Pacific

- Richer mix drives higher gross margins

12\% Growth in Operating Income

|  | Q3 2015 <br> $\mathbf{\$ m}$ | Q3 2016 <br> $\mathbf{\$ m}$ | Growth <br> $\%$ |
| :--- | ---: | ---: | ---: |
| Net sales | 121.3 | 114.4 | $(6) \%$ |
| Gross profit | 39.5 | 43.8 | $11 \%$ |
| Gross margin | $32.6 \%$ | $38.3 \%$ | $5.7 \% \mathrm{pt}$ |
| Operating income | 21.6 | 24.1 | $12 \%$ |
| EBITDA | 22.5 | 25.2 | $12 \%$ |

## Q3 2016 Performance Chemicals

Continued excellent growth, based on both existing and new products
Personal Care growth drives richer mix and improved margins

- Business well positioned to combine with new acquisition

| Q3 2015 |
| :--- | ---: | ---: | ---: |
| $\$ \mathrm{~m}$ |$\quad$| Q3 2016 |
| ---: |
| $\$ \mathrm{~m}$ |$\quad$| Growth |
| ---: |
| $\%$ |

## Q3 2016 Oilfield Services

- Business break-even in the quarter
- Sales down on 2015 but up 7\% sequentially on Q2
- Customer activity picking up slowly

| Q3 2015 |
| :--- | ---: | ---: | ---: |
| $\$ \mathrm{~m}$ |$\quad$| Q3 2016 |
| ---: |
| $\$ \mathrm{~m}$ |$\quad$| Growth |
| ---: |
| $\%$ |

## Q3 2016 Octane Additives

- Sales down on very strong comparative quarter
- Last portion of Algeria order delayed until October
- No further visibility on orders

|  | Q3 2015 <br> \$m | Q3 2016 <br> $\$ m$ | Growth <br> $\%$ |
| :--- | ---: | ---: | ---: |
| Net sales | 20.3 | 4.6 | $(77) \%$ |
| Gross profit | 9.0 | 2.5 | $(72) \%$ |
| Gross margin | $44.3 \%$ | $54.3 \%$ | $10.0 \%$ pt |
| Operating income | 8.0 | 1.9 | $(76) \%$ |
| EBITDA | 8.1 | 2.0 | $(75) \%$ |

## Q3 2016 Corporate Items

Significant impact of one-off items on EPS

- Underlying corporate costs in expected range
- Tax rate for year expected to be $\mathbf{2 0 \%}$

|  | Q3 2015 <br> $\$ \mathrm{\$ m}$ | Q3 2016 <br> $\$ \mathrm{~m}$ |
| :--- | ---: | ---: |
| Corporate costs | $(9.3)$ | $(15.2)$ |
| Pension credit | - | 1.6 |
| Adjustment to fair value of contingent consideration | 8.5 | 2.3 |
| Profit on disposal of subsidiary | 1.6 | - |
| GAAP effective tax rate | $14.0 \%$ | $13.6 \%$ |

## Q3 2016 Balance Sheet

Balance sheet remains very strong
\$29.8 million of cash generation; net cash of $\mathbf{\$ 1 9 . 6}$ million
Further increase in semi-annual dividend

|  | Q4 2015 | Q3 2016 |
| :--- | ---: | ---: |
| $\$ \mathrm{~m}$ | $\$ \mathrm{~m}$ |  |
| Total cash and cash equivalents | 141.7 | 167.1 |
| Total debt | $(136.1)$ | $(147.5)$ |
| Net cash | 5.6 | 19.6 |
| Total working capital | 167.1 | 160.4 |



## Concluding Comments

- Business performance on-track
- EPS impacted by one-off items
- Business continues to grow and generate good cash
-Acquisition from Huntsman - on track for Q4
- Increase in semi-annual dividend
- Very well placed for Quarter 4, and for 2017


## Your Opportunity To Ask Questions

## innospec

## Final Comments

- Thanks to investors, customers and employees for their continued support
- Q4 2016 results timetable (provisional)
- Results announced after close on February 16, 2016

Conference Call at 10am ET on Friday February 17, 2016

## Appendix

## innospec

## Innospec Income Statement - Quarter 3

|  | $\begin{array}{r} \text { Q3 } 2015 \\ \$ \mathrm{~m} \end{array}$ | $\begin{array}{r} \text { Q3 } 2016 \\ \text { \$m } \end{array}$ | Variance Pr. Yr. \$m |
| :---: | :---: | :---: | :---: |
| Net sales | 254.2 | 205.5 | (48.7) |
| Sales growth | 11.4\% | (19.2)\% | N/A |
| Gross profit | 90.4 | 79.2 | (11.2) |
| Gross margin | 35.6\% | 38.5\% | 2.9\%pt |
| SAR expenses | (59.3) | (62.6) | (3.3) |
| Operating income | 31.1 | 16.6 | (14.5) |
| Operating margin | 12.2\% | 8.1\% | (4.1\%) pt |
| Adjustment to fair value of contingent consideration | 8.5 | 2.3 | (6.2) |
| Profit on disposal of subsidiary | 1.6 |  | (1.6) |
| Interest expense, net | (1.0) | (0.7) | 0.3 |
| Other net income/(expense) | 1.2 | (5.0) | (6.2) |
| Income before income taxes | 41.4 | 13.2 | (28.2) |
| Income taxes | (5.8) | (1.8) | 4.0 |
| Net income | 35.6 | 11.4 | (24.2) |
| Adjusted EBITDA | 42.1 | 21.2 | (20.9) |
| Adjusted EBITDA margin | 16.6\% | 10.3\% | (6.3\%)pt |

## Innospec Income Statement - YTD

| Net sales | $\begin{array}{r} 2015 \\ \$ \mathrm{~m} \\ \\ 766.3 \end{array}$ | $\begin{array}{r} 2016 \\ \$ \mathrm{~m} \\ \\ 645.6 \end{array}$ | Variance Pr. Yr. (120.7) |
| :---: | :---: | :---: | :---: |
| Sales growth | 14.3\% | (15.8\%) | N/A |
| Gross profit | 259.7 | 240.9 | (18.8) |
| Gross margin | 33.9\% | 37.3\% | 3.4\%pt |
| SAR expenses | (170.9) | (172.7) | (1.8) |
| Operating income | 88.8 | 68.2 | (20.6) |
| Operating margin | 11.6\% | 10.6\% | (1.0\%)pt |
| Adjustment to fair value of contingent consideration | 31.6 | 6.3 | (25.3) |
| Profit/(loss) on disposal of subsidiary | 1.6 | (1.4) | (3.0) |
| Interest expense, net | (2.9) | (2.2) | 0.7 |
| Other net (expense)/income | (2.0) | 3.2 | 5.2 |
| Income before income taxes | 117.1 | 74.1 | (43.0) |
| Income taxes | (29.1) | (14.9) | 14.2 |
| Net income | 88.0 | 59.2 | (28.8) |
| Adjusted EBITDA | 113.5 | 98.3 | (15.2) |
| Adjusted EBITDA margin | 14.8\% | 15.2\% | 0.4\%pt |

innospec

## Fuel Specialties - Quarter 3

|  | $\begin{array}{r} \text { Q3 } 2015 \\ \$ \mathbf{m} \end{array}$ | $\begin{array}{r} \text { Q3 } 2016 \\ \$ \mathbf{m} \end{array}$ | Variance Pr. Yr. \$m |
| :---: | :---: | :---: | :---: |
| Net sales | 121.3 | 114.4 | (6.9) |
| Sales growth | (7.4\%) | (5.7\%) | N/A |
| Gross profit | 39.5 | 43.8 | 4.3 |
| Gross margin | 32.6\% | 38.3\% | 5.7\%pt |
| Selling | (10.6) | (11.4) | (0.8) |
| Administrative | (2.9) | (4.1) | (1.2) |
| Research | (4.4) | (4.2) | 0.2 |
| SAR expenses | (17.9) | (19.7) | (1.8) |
| SAR\% | (14.8\%) | (17.2\%) | (2.4\%)pt |
| Operating income | 21.6 | 24.1 | 2.5 |
| Operating income margin | 17.8\% | 21.1\% | 3.3\%pt |
| EBITDA | 22.5 | 25.2 | 2.7 |
| EBITDA margin | 18.5\% | 22.0\% | 3.5\%pt |

innospec

## Fuel Specialties - YTD

|  | $\begin{array}{r} 2015 \\ \$ \mathrm{~m} \end{array}$ | $\begin{array}{r} 2016 \\ \$ \mathrm{~m} \end{array}$ | Variance Pr. Yr. <br> \$m |
| :---: | :---: | :---: | :---: |
| Net sales | 386.6 | 367.1 | (19.5) |
| Sales growth | (5.7\%) | (5.0\%) | N/A |
| Gross profit | 125.4 | 129.5 | 4.1 |
| Gross margin | 32.4\% | 35.3\% | 2.9\%pt |
| Selling | (32.1) | (31.9) | 0.2 |
| Administrative | (9.3) | (12.2) | (2.9) |
| Research | (13.3) | (13.2) | 0.1 |
| SAR expenses | (54.7) | (57.3) | (2.6) |
| SAR\% | (14.1\%) | (15.6\%) | (1.5\%)pt |
| Operating income | 70.7 | 72.2 | 1.5 |
| Operating income margin | 18.3\% | 19.7\% | 1.4\%pt |
| EBITDA | 73.7 | 75.7 | 2.0 |
| EBITDA margin | 19.1\% | 20.6\% | 1.5\%pt |

innospec

## Performance Chemicals - Quarter 3

|  | $\begin{array}{r} \text { Q3 } 2015 \\ \$ \mathrm{~m} \end{array}$ | $\begin{array}{r} \text { Q3 } 2016 \\ \$ \mathbf{m} \end{array}$ | Variance Pr. Yr. \$m |
| :---: | :---: | :---: | :---: |
| Net sales | 33.7 | 36.8 | 3.1 |
| Sales growth | (27.1\%) | 9.2\% | N/A |
| Gross profit | 9.9 | 12.3 | 2.4 |
| Gross margin | 29.4\% | 33.4\% | 4.0\%pt |
| Selling | (3.0) | (4.6) | (1.6) |
| Administrative | (2.0) | (2.1) | (0.1) |
| Research | (1.3) | (1.4) | (0.1) |
| SAR expenses | (6.3) | (8.1) | (1.8) |
| SAR \% | (18.7\%) | (22.0\%) | (3.3\%)pt |
| Operating income | 3.6 | 4.2 | 0.6 |
| Operating income margin | 10.7\% | 11.4\% | 0.7\%pt |
| EBITDA | 5.1 | 5.8 | 0.7 |
| EBITDA margin | 15.1\% | 15.8\% | 0.7\%pt |

## Performance Chemicals - YTD

|  | $\begin{array}{r} 2015 \\ \$ \mathrm{~m} \end{array}$ | $\begin{array}{r} 2016 \\ \$ \mathrm{~m} \end{array}$ | Variance Pr. Yr. \$m |
| :---: | :---: | :---: | :---: |
| Net sales | 124.4 | 106.8 | (17.6) |
| Sales growth | (8.9\%) | (14.1\%) | N/ |
| Gross profit | 33.3 | 34.4 | 1.1 |
| Gross margin | 26.8\% | 32.2\% | 5.4\%pt |
| Selling | (10.0) | (12.2) | (2.2) |
| Administrative | (6.6) | (5.4) | 1.2 |
| Research | (3.6) | (3.5) | 0.1 |
| SAR expenses | (20.2) | (21.1) | (0.9) |
| SAR\% | (16.2\%) | (19.8\%) | (3.6\%) pt |
| Operating income | 13.1 | 13.3 | 0.2 |
| Operating income margin | 10.5\% | 12.5\% | 2.0\%pt |
| EBITDA | 17.8 | 18.0 | 0.2 |
| EBITDA margin | 14.3\% | 16.9\% | 2.6\%pt |

## Oilfield Services - Quarter 3

|  | $\begin{array}{r} \text { Q3 } 2015 \\ \text { \$m } \end{array}$ | $\begin{array}{r} \text { Q3 } 2016 \\ \$ \mathrm{~m} \end{array}$ | Variance Pr. Yr |
| :---: | :---: | :---: | :---: |
| Net sales | 78.9 | 49.7 | (29.2) |
| Sales growth | 119.8\% | (37.0\%) | N/ |
| Gross profit | 32.0 | 20.6 | (11.4) |
| Gross margin | 40.6\% | 41.4\% | 0.8\%pt |
| Selling | (19.3) | (16.8) | 2.5 |
| Administrative | (4.6) | (2.9) | 1.7 |
| Research | (0.9) | (0.9) |  |
| SAR expenses | (24.8) | (20.6) | 4.2 |
| SAR\% | (31.4\%) | (41.4\%) | (10.0\%)pt |
| Operating income | 7.2 |  | (7.2) |
| Operating income margin | 9.1\% |  | (9.1\%) pt |
| EBITDA | 11.7 | 4.6 | (7.1) |
| EBITDA margin | 14.8\% | 9.3\% | (5.5\%)pt |

## Oilfield Services - YTD

|  | $\begin{array}{r} 2015 \\ \$ \mathrm{~m} \end{array}$ | $\begin{array}{r} 2016 \\ \$ m \end{array}$ | Variance Pr. Yr. \$m |
| :---: | :---: | :---: | :---: |
| Net sales | 216.3 | 132.4 | (83.9) |
| Sales growth | 136.4\% | (38.8\%) | N/ |
| Gross profit | 82.4 | 52.1 | (30.3) |
| Gross margin | 38.1\% | 39.4\% | 1.3\%pt |
| Selling | (53.8) | (48.7) | 5.1 |
| Administrative | (12.4) | (7.6) | 4.8 |
| Research | (2.4) | (2.9) | (0.5) |
| SAR expenses | (68.6) | (59.2) | 9.4 |
| SAR\% | (31.7\%) | (44.7\%) | (13.0\%)pt |
| Operating income | 13.8 | (7.1) | (20.9) |
| Operating income margin | 6.4\% | (5.4\%) | (11.8\%)pt |
| EBITDA | 27.0 | 6.4 | (20.6) |
| EBITDA margin | 12.5\% | 4.8\% | (7.7\%)pt |

innospec

## Octane Additives - Quarter 3

|  | $\text { Q3 } \begin{array}{r} 2015 \\ \$ \mathrm{~m} \end{array}$ | $\begin{array}{r} \text { Q3 } 2016 \\ \$ \mathrm{~m} \end{array}$ | Variance Pr. Yr. \$m |
| :---: | :---: | :---: | :---: |
| Net sales | 20.3 | 4.6 | (15.7) |
| Sales growth | 34.4\% | (77.3\%) | N/ |
| Gross profit | 9.0 | 2.5 | (6.5) |
| Gross margin | 44.3\% | 54.3\% | 10.0\%pt |
| Selling | (0.4) | (0.2) | 0.2 |
| Administrative | (0.6) | (0.4) | 0.2 |
| SAR expenses | (1.0) | (0.6) | 0.4 |
| SAR\% | (4.9\%) | (13.0\%) | (8.1\%)pt |
| Operating income | 8.0 | 1.9 | (6.1) |
| Operating income margin | 39.4\% | 41.3\% | 1.9\%pt |
| EBITDA | 8.1 | 2.0 | (6.1) |
| EBITDA margin | 39.9\% | 43.5\% | 3.6\%pt |

## Octane Additives - YTD

|  | $\begin{array}{r} 2015 \\ \$ \mathrm{~m} \end{array}$ | $\begin{array}{r} 2016 \\ \$ m \end{array}$ | Variance Pr. Yr. \$m |
| :---: | :---: | :---: | :---: |
| Net sales | 39.0 | 39.3 | 0.3 |
| Sales growth | 20.7\% | 0.8\% | N/A |
| Gross profit | 18.6 | 24.9 | 6.3 |
| Gross margin | 47.7\% | 63.4\% | 15.7\%pt |
| Selling | (1.1) | (0.7) | 0.4 |
| Administrative | (1.6) | (1.7) | (0.1) |
| SAR expenses | (2.7) | (2.4) | 0.3 |
| SAR \% | (6.9\%) | (6.1\%) | 0.8\%pt |
| Operating income | 15.9 | 22.5 | 6.6 |
| Operating income margin | 40.8\% | 57.3\% | 16.5\%pt |
| EBITDA | 16.2 | 22.9 | 6.7 |
| EBITDA margin | 41.5\% | 58.3\% | 16.8\%pt |

## GAAP Reconciliation Adjusted EBITDA - Quarter 3

|  | Q3 2015 |  |
| :--- | ---: | ---: | ---: |
| $\$ \mathrm{\$ m}$ | Q3 2016 |  |
| $\$ \mathrm{~m}$ |  |  |
| Net income | 35.6 | 11.4 |
| Interest expense, net | 1.0 | 0.7 |
| Income taxes | 5.8 | 1.8 |
| Depreciation and amortization | 8.2 | 9.6 |
| Adjustment to fair value of contingent consideration | $(8.5)$ | $(2.3)$ |
| Adjusted EBITDA | 42.1 | 21.2 |

innospec

## GAAP Reconciliation Adjusted EBITDA - YTD

|  | 2015 | 2016 |
| :--- | ---: | ---: | ---: |
| $\mathbf{\$ m}$ | $\$ \mathrm{~m}$ |  |
| Net Income | 88.0 | 59.2 |
| Interest expense, net | 2.9 | 2.2 |
| Income taxes | 29.1 | 14.9 |
| Depreciation and amortization | 25.1 | 28.3 |
| Adjustment to fair value of contingent consideration | $(31.6)$ | $(6.3)$ |
| Adjusted EBITDA | 113.5 | 98.3 |

## GAAP Reconciliation: Net Income Excluding Special Items - Quarter 3

|  | Income before income taxes \$m | Net income \$m | Diluted EPS | Income before income taxes \$m | Net income \$m | Diluted EPS |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Reported GAAP amounts | 41.4 | 35.6 | 1.45 | 13.2 | 11.4 | 0.47 |
| Foreign currency exchange (gains)/losses | (1.2) | (0.9) | (0.04) | 5.0 | 4.3 | 0.18 |
| Amortization of acquired intangible assets | 4.3 | 3.4 | 0.14 | 4.3 | 3.7 | 0.15 |
| Adjustment to fair value of contingent consideration | (8.5) | (4.8) | (0.20) | (2.3) | (1.4) | (0.06) |
| Acquisition-related costs | - | - | - | 1.7 | 1.7 | 0.07 |
| Adjustment of income tax provisions | (2.7) | (2.7) | (0.11) | (1.2) | (1.2) | (0.05) |
| Settlement of distributor claim | - | - | - | 1.0 | 0.6 | 0.02 |
| Profit on disposal of subsidiary | (1.6) | (1.6) | (0.06) | - | - |  |
| Adjusted non-GAAP amounts | 31.7 | 29.0 | 1.18 | 21.7 | 19.1 | 0.78 |

innospec

